Clinical Trials Browser

INDUSTRY × Neutropenia × Breast × Clear all

Breast Neoplasms, Neutropenia

Breast Neoplasms, Neutropenia

Breast Neoplasms, Neutropenia

Alopecia, Breast Neoplasms, Neutropenia

Breast Neoplasms, Neutropenia

Breast Neoplasms, Neutropenia

Breast Neoplasms, Neutropenia, Chemotherapy-Induced Febrile Neutropenia

Breast Neoplasms, Neutropenia

Breast Neoplasms, Neutropenia

Breast Neoplasms, Neutropenia

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Neutropenia, Febrile Neutropenia

Breast Neoplasms, Neutropenia

Breast Neoplasms, Neutropenia

Breast Neoplasms, Neutropenia

Breast Neoplasms, Neutropenia

Breast Neoplasms, Neutropenia

Breast Neoplasms, Neutropenia, Febrile Neutropenia

Breast Neoplasms, Neutropenia, Febrile Neutropenia

Breast Neoplasms, Neutropenia

Breast Neoplasms, Neutropenia

Breast Neoplasms, Neutropenia, Febrile Neutropenia

Breast Neoplasms, Neutropenia

Breast Neoplasms, Neutropenia, Febrile Neutropenia

Breast Neoplasms, Lung Neoplasms, Lymphoma, Non-Hodgkin, Neutropenia, Ovarian Neoplasms

Breast Neoplasms, Neoplasms, Neutropenia

Breast Neoplasms, Fever, Neutropenia

Breast Neoplasms, Neutropenia

Breast Neoplasms, Neoplasms, Neutropenia

Clinical Trials

Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer

Study of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

Neulasta-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

A Study of ALRN-6924 for Protection of Chemotherapy-Induced Side Effects in Patients With TP53-Mutant Breast Cancer

ADVANCE

SPI-2012 vs Pegfilgrastim in Management of Neutropenia in Breast Cancer Participants With Docetaxel and Cyclophosphamide

Efficacy and Safety Study With MYL-1401H and Neulasta

Placebo-controlled Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

Recombinant Human Serum Albumin/Granulocyte Colony Stimulating Factor Fusion Protein for Breast Cancer Patients

Dose-Finding Trial of F-627 in Women With Breast Cancer Receiving Myelotoxic Chemotherapy

Safety and Efficacy of YPEG-rhG-CSF in Cancer Patients Receiving Chemotherapy

Pegfilgrastim-gema Compared to Pegfilgrastim-roche for Prevention of Induced Neutropenia in Breast Cancer Patients.

PROTECT2

Study to Assess the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of GW003 in Patients With Breast Cancer

Fusion Protein rHSA/GCSFclinical Study on Breast Cancer Patients

PROTECT-1

Dose-finding Study of Empegfilgrastim for Neutropenia Prophylaxis in Patients With Breast Cancer

Study of the Efficacy and Safety of Empegfilgrastim for Neutropenia Prophylaxis in Breast Cancer Patients

Study on Efficacy and Safety of CBLB612 for Neutropenia Prophylaxis

PIONEER

A Phase II Study Comparing Pegylated rhG-CSF（HHPG-19K） and rhG-CSF in Breast Cancer Patients Receiving Chemotherapy

Pegfilgrastim as Support to Advanced Breast Cancer Patients Receiving Chemotherapy

A Study Comparing Pegylated rhG-CSF and rhG-CSF as Support to Breast Cancer Patients Receiving Chemotherapy

A Study of Primary Prophylaxis With Neulasta (Pegfilgrastim) Versus Secondary Prophylaxis After Chemotherapy in Elderly Subjects (>/= 65 Years Old) With Cancer

A Study of Cyclophosphamide/Methotrexate/5-Fluorouracil (CMF) With Pegfilgrastim in Subjects With Breast Cancer

Same Day Dosing of Pegfilgrastim in Breast Cancer Patients Undergoing Chemotherapy (TAC)

Treatment for Elderly Patients With High Risk Breast Cancer

Evaluation of Maxy-G34 in Breast Cancer Patients Treated With TAC (Docetaxel, Adriamycin, Cyclophosphamide) Chemotherapy